[C-11]NPA PET-amphetamine in Cocaine Use Disorders
ConditionCocaine Use Disorder
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-55
SponsorRajesh Narendran
About this trial
This study uses \[11C\]NPA positron emission tomography (PET) and a d-amphetamine challenge to image amphetamine induced dopamine release in the striatum in subjects with cocaine use disorders (CUD). Amphetamine-induced dopamine release data from this study will be correlated with \[11C\]NOP-1A VT measured at baseline in the midbrain. \[11C\]NOP-1A PET data will be used from aim 1 (see, Study Record: Imaging CRF X NOP interactions in Cocaine Use Disorders)
Eligibility criteria
Qualifiers
Males or females between 18 and 55 years old
Fulfil DSM-5 criteria for cocaine use disorder
No other current DSM-5 psychiatric or addictive disorders (such as major depressive disorder, bipolar disorders, psychotic disorders, etc.,)
No current abuse (six months) of opiates, sedative-hypnotics, amphetamines, and MDMA as well as moderate to severe alcohol or cannabis use (twice a week). Nicotine use will be quantified and controlled between groups using the Fagerstrom Test for Nicotine Dependence (Heatherton et al., 1991);
Disqualifiers
None
Trial design
Treatments tested in this trial
- Baseline [C-11]NPA PET Scan
- d-amphetamine
- Post-amphetamine [C-11]NPA PET Scan
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Rajesh Narendran
Lead sponsor
University of Pittsburgh
Sponsor institution
National Institute on Drug Abuse (NIDA)
Collaborator
Source ClinicalTrials.gov